Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15146937 | 1.00 | KMT2A (0.59) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL17971009 | 1.00 | KMT2A (0.59) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL16769614 | 0.91 | KMT2A (0.56) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL26032361 | 0.89 | KMT2A (0.58) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL23042742 | 0.89 | KMT2A (0.57) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL13403896 | 0.89 | KMT2A (0.70) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL34141 | 0.89 | KMT2A (0.70) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL989366 | 0.89 | KMT2A (0.70) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL17843660 | 0.89 | KMT2A (0.70) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL2531873 | 0.89 | KMT2A (0.70) | KMT2AEPHX2LMNASMN1; SMN2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239537-A1 | APELIN PEPTIDES AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239537-A1 | APELIN PEPTIDES AND USES THEREOF | APLNR, MME, ANPEP | KMT2A 2137/4885EPHX2 2632/4885LMNA 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.